TS
VRTX icon

Thomas Steyer’s Vertex Pharmaceuticals VRTX Stock Holding History

Thomas Steyer’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-55,000
Closed -$22.4M – 188
2023
Q4 		$22.4M Sell
55,000
-147,000
-73% -$54.3M 0.1% 68
2023
Q3 		$70.2M Buy
+202,000
New +$70.6M 0.33% 51

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Thomas Steyer's VRTX Position: Q1 2024 in Review

Thomas Steyer sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 55,000 shares — an estimated $22.4M sold.

Thomas Steyer first reported a position in VRTX in Q3 2023 and held it in 2 quarters. The position peaked at $70.2M in Q3 2023. 1,495 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Thomas Steyer reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Thomas Steyer sold 55,000 Vertex Pharmaceuticals shares in Q1 2024, an estimated $22.4M.
  • Thomas Steyer first reported a position in Vertex Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Thomas Steyer's Vertex Pharmaceuticals position peaked at $70.2M in Q3 2023.
  • 1,495 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Farallon Capital Management's 13F filing for Q1 2024, filed 15 May 2024.